Transactions with warrants of series TO 1 in Curasight A/S made by managerial employees and their closely associated persons
COPENHAGEN – Curasight A/S (“Curasight” or “the Company”). In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Curasight made by managerial employees and their closely associated persons.
The Company’s managerial employees and their closely associated persons have given Curasight’s power of attorney on their behalf to publish trading in Curasight’s warrants of series TO 1 by the Company’s managerial employees and their closely associated persons. Curasight’s managerial employees and their closely associated persons have exercised all their warrants of series TO 1.
The warrants of series TO 1 were issued in connection with the Company’s IPO in September 2020. The transactions comprise all (100%) available warrants of series TO 1 of the following managerial employees and their closely associated persons;
| Name | Position | Aggregated volume | Price, DKK |
| Per Falholt | Chairman of the Board of directors | 30,380 | 522,536.00 |
| Lars Trolle | Deputy chairman of the Board of directors | 9,114 | 156,760.80 |
|
Charlotte Vedel |
Member of the Board of directors |
24,304 |
418,028,80 |
| Andreas Kjær | CSO and member of the Board of directors | 6,076 | 104,507.20 |
|
Ulrich Krasilnikoff |
CEO and member of the Board of directors |
6,076 |
104,507.20 |
| Total | 75,950 | 1,306,340.00 |
Curasight issued units (shares and consideration free warrants) in connection with the Company’s IPO in September 2020, as well as the Private Placement that was executed in parallel with the IPO. Each unit consisted of eight shares and seven warrants. During the exercise period for the warrants of series TO 1, each warrant holder has the possibility, for each warrant, to subscribe for one new share in Curasight for DKK 17.20 per share. The exercise period ends on 7 October 2021.
The proceeds that the Company will receive through the warrant exercise will finance Curasight’s clinical development plan.
For further information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.